This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (20)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Initial Dosimetry Results

Kenneth H. Cohn, MD; Sydney Welt, MD; William P. Banner, MD; Martin Harrington, MD; Samuel Yeh, MD; Junichi Sakamoto, MD; Carlos Cardon-Cardo, MD, PhD; John Daly, MD; Nancy Kemeny, MD; Alfred Cohen, MD; Kenneth Lloyd, PhD; Jerome DeCosse, MD, PhD; Herbert Oettgen, MD; Lloyd Old, MD

Arch Surg. 1987;122(12):1425-1429.

Abstract
• HT-29-15 is an IgG1 monoclonal antibody reacting with a neuraminidase-sensitive determinant on a cell-surface antigen (molecular weight, 200 000 daltons) present on the colon cancer cell line HT-29. HT-29-15 was selected for a tumor localization study because the antigen was shown to be present, by immunohistochemical staining, in a high percentage of primary and metastatic colorectal cancers. HT-29-15 labeled with iodine 131 was given intravenously over a dose range of 0.2 to 10.0 mg to 23 patients with colorectal cancer. No significant toxicity was seen. Imaging of hepatic metastases was successful from days 5 to 7. Analysis of tissue radioactivity by biopsy showed that the tumor-liver ratio increased from day 1 to day 7, suggesting more rapid clearance of antibody from normal tissue than from tumor. Thus, tissue biopsy specimens and scintigraphy have shown that imaging of metastatic colorectal cancer is possible with monoclonal antibody HT-29-15. Tissue biopsy specimens are essential for demonstrating specificity of localization. Scans alone provide insufficient evidence of specific localization by monoclonal antibodies. Simultaneous infusion of a nonreactive control antibody would be necessary for specific localization to be demonstrated unequivocally.

(Arch Surg 1987;122:1425-1429)

Author Affiliations
From the Departments of Surgery (Drs Cohn, Banner, Harrington, Daly, Cohen, and DeCosse), Medicine (Drs Welt, Kemeny, Sakamoto, Oettgen, Lloyd, and Old), Pathology (Dr Cardon-Cardo), and Radiology (Dr Yeh), Memorial Sloan-Kettering Cancer Center, New York.

Footnotes
Accepted for publication Aug 12, 1987.

Read before the Annual Meeting of the Society of Surgical Oncology, London, April 30, 1987.

Reprint requests to Department of Tumor Immunology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10221 (Dr Old).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors
Yuan et al.
Molecular Cancer Therapeutics 2009;8:1906-1915.
ABSTRACT | FULL TEXT